ObsEva
ObsEva
  • Home
  • Our Science
    • ART
    • Uterine Fibroids
    • Endometriosis
    • Preterm Labor
    • Obseva Publications
  • Our Pipeline
    • Overview
    • Nolasiban
    • Linzagolix
    • OBE022
  • Partnering
  • Investors
    • Company Profile
    • Financial Reports
    • Stock Data
    • SEC Filings
    • Corporate Governance
    • Event Calendar
    • General Meetings
    • Press Releases
    • Sign Up For News
  • Our Company
    • Work With Us
    • Leadership Team
    • Scientific Advisory Board
  • PR – ObsEva Publications – Media – Events
    • Press Releases
    • Obseva Publications
    • Media
    • Events
  • Contact
Skip to content
  • Our Company
    • Work With Us
    • Leadership Team
    • Scientific Advisory Board
  • PR – ObsEva Publications – Media – Events
    • Press Releases
    • Obseva Publications
    • Media
    • Events
  • Contact
Skip to content
ObsEva
  • Home
  • Our Science
    • ART
    • Uterine Fibroids
    • Endometriosis
    • Preterm Labor
    • Obseva Publications
  • Our Pipeline
    • Overview
    • Nolasiban
    • Linzagolix
    • OBE022
  • Partnering
  • Investors
    • Company Profile
    • Financial Reports
    • Stock Data
    • SEC Filings
    • Corporate Governance
    • Event Calendar
    • General meetings
    • Press Releases
    • Sign Up For News

Month: February 2018

Confirmation of the Cardiac Safety of PGF2α Receptor Antagonist OBE022 in a First-in-Human Study in Healthy Subjects, Using Intensive ECG Assessments

Posted on February 28, 2018 (June 25, 2019) by Sylwia Scheel-Krüger

Jörg Täubel, Ulrike Lorch, Simon Coates, Sara Fernandes, Paul Foley, Georg Ferber, Jean-Pierre Gotteland, Oliver Pohl Confirmation of the Cardiac…

Posted in Content, PublicationsTagged OBE022Leave a comment

ObsEva SA Reports Positive Topline Results from IMPLANT2 Phase 3 Clinical Trial of Nolasiban in IVF

Posted on February 26, 2018 (June 18, 2019) by Sylwia Scheel-Krüger

The WHO considers infertility a global public health issue affecting 186 million people, and only 1 in 4 ART treatments…

Posted in Content, Press releaseTagged 2018Leave a comment

ObsEva Investor Conference Call

Posted on February 26, 2018 (June 8, 2019) by Sylwia Scheel-Krüger
Posted in Content, EventsTagged 2018Leave a comment

ObsEva SA to Hold Investor Call to announce Topline Results of the IMPLANT2 phase 3 Clinical Trial of Nolasiban in IVF/ICSI on Monday February 26, 2018

Posted on February 23, 2018 (June 18, 2019) by Sylwia Scheel-Krüger

Geneva, Switzerland and Boston, MA – February 23, 2018 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics…

Posted in Content, Press releaseTagged 2018Leave a comment

LEERINK Partners 7th Annual Global Healthcare Conference

Posted on February 14, 2018 (June 8, 2019) by Sylwia Scheel-Krüger
Posted in Content, EventsTagged 2018Leave a comment

ObsEva SA to present at the LEERINK Partners 7th Annual Global Healthcare Conference February 14th 2018

Posted on February 7, 2018 (June 18, 2019) by Sylwia Scheel-Krüger

Geneva, Switzerland and Boston, MA – February 7, 2018 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics…

Posted in Content, Press releaseTagged 2018Leave a comment

Dr. Ernest Loumaye, CEO of ObsEva SA returns to work following a personal leave for medical reasons

Posted on February 1, 2018 (June 18, 2019) by Sylwia Scheel-Krüger

Geneva, Switzerland and Boston, MA – February 1, 2018– ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics…

Posted in Content, Press releaseTagged 2018Leave a comment

Recent Posts

  • ObsEva to participate in The 10th Annual Jefferies Global Healthcare Conference, November 20-21, 2019
  • Investor Presentation 10th Annual Jefferies Global Healthcare Conference 21 November 2019
  • ObsEva to participate in The Credit Suisse Healthcare Conference, November 11-13, 2019
  • Investor Presentation November 2019
  • Third Quarter 2019 Financial Results 7 November 2019

Recent Comments

    Archives

    • November 2019
    • October 2019
    • September 2019
    • August 2019
    • July 2019
    • June 2019
    • May 2019
    • April 2019
    • March 2019
    • February 2019
    • January 2019
    • December 2018
    • November 2018
    • October 2018
    • September 2018
    • August 2018
    • July 2018
    • June 2018
    • May 2018
    • April 2018
    • March 2018
    • February 2018
    • January 2018
    • December 2017
    • November 2017
    • October 2017
    • September 2017
    • August 2017
    • July 2017
    • June 2017
    • May 2017
    • April 2017
    • March 2017
    • February 2017
    • January 2017
    • October 2016
    • August 2016
    • July 2016
    • May 2016
    • April 2016
    • March 2016
    • November 2015
    • October 2015
    • September 2015
    • June 2015
    • March 2015
    • February 2015
    • November 2014
    • September 2014
    • July 2014
    • January 2014
    • August 2013
    • January 2000

    Categories

    • ART
    • Board of Directors
    • Clinical studies
    • Committee
    • company profile
    • Contact
    • Content
    • Corporate governance
    • Endometriosis
    • event calendar
    • event form
    • Events
    • Financial Report
    • Governance Documents
    • homepage
    • Interview with Ernest Loumaye
    • Investor Presentations
    • Investors landingpage
    • Leadership Team
    • Linzagolix
    • Media
    • Nolasiban
    • OBE022
    • ObsEva General Meetings
    • Our pipeline overview
    • Page block
    • Partnering
    • Press release
    • Preterm Labor
    • privacy policy
    • Publications
    • Scientific Advisory Board
    • Sign up for news
    • Terms
    • Uterine Fibroids
    • Work with us

    Meta

    • Log in
    • Entries RSS
    • Comments RSS
    • WordPress.org
     
    • Our Science
    • Our Pipeline
    • Partnering
    • Investors
    • Our Company
    • ObsEva Publications
    • Press Releases
    • Contact: 

    Follow us on LinkedIn

    Sign up for news

    Copyright © 2019 ObsEva - All rights reserved.

    Terms - Privacy Policy